Bank of New York Mellon’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-252,354
| Closed | -$4.68M | – | 4436 |
|
|
2023
Q3 | $4.68M | Buy |
252,354
+34,189
| +16% | +$387K | ﹤0.01% | 2351 |
|
|
2023
Q2 | $2.41M | Buy |
218,165
+42,384
| +24% | +$591K | ﹤0.01% | 2731 |
|
|
2023
Q1 | $2.36M | Sell |
175,781
-18,502
| -10% | -$320K | ﹤0.01% | 2707 |
|
|
2022
Q4 | $2.4M | Buy |
194,283
+89,119
| +85% | +$1.26M | ﹤0.01% | 2750 |
|
|
2022
Q3 | $1.47M | Buy |
105,164
+6,857
| +7% | +$110K | ﹤0.01% | 3022 |
|
|
2022
Q2 | $1.36M | Sell |
98,307
-7,422
| -7% | -$119K | ﹤0.01% | 3050 |
|
|
2022
Q1 | $1.72M | Buy |
105,729
+2,644
| +3% | +$41.4K | ﹤0.01% | 3019 |
|
|
2021
Q4 | $1.68M | Buy |
103,085
+9,863
| +11% | +$166K | ﹤0.01% | 3094 |
|
|
2021
Q3 | $1.38M | Buy |
93,222
+12,723
| +16% | +$204K | ﹤0.01% | 3216 |
|
|
2021
Q2 | $1.61M | Sell |
80,499
-22,191
| -22% | -$440K | ﹤0.01% | 3141 |
|
|
2021
Q1 | $2.37M | Sell |
102,690
-2,344
| -2% | -$65.3K | ﹤0.01% | 2834 |
|
|
2020
Q4 | $2.59M | Sell |
105,034
-585
| -0.6% | -$19.4K | ﹤0.01% | 2687 |
|
|
2020
Q3 | $4.38M | Sell |
105,619
-4,941
| -4% | -$227K | ﹤0.01% | 2289 |
|
|
2020
Q2 | $5.3M | Buy |
110,560
+3,904
| +4% | +$302K | ﹤0.01% | 2183 |
|
|
2020
Q1 | $6.71M | Sell |
106,656
-7,839
| -7% | -$704K | ﹤0.01% | 1912 |
|
|
2019
Q4 | $14.2M | Buy |
114,495
+15,445
| +16% | +$1.38M | ﹤0.01% | 1774 |
|
|
2019
Q3 | $6.57M | Sell |
99,050
-1,213
| -1% | -$81.5K | ﹤0.01% | 2153 |
|
|
2019
Q2 | $7.98M | Buy |
100,263
+4,707
| +5% | +$421K | ﹤0.01% | 2090 |
|
|
2019
Q1 | $10.7M | Buy |
95,556
+1,137
| +1% | +$124K | ﹤0.01% | 1937 |
|
|
2018
Q4 | $9.52M | Buy |
94,419
+1,192
| +1% | +$124K | ﹤0.01% | 1932 |
|
|
2018
Q3 | $11.8M | Buy |
93,227
+3,342
| +4% | +$354K | ﹤0.01% | 1926 |
|
|
2018
Q2 | $7.54M | Buy |
89,885
+18,340
| +26% | +$1.34M | ﹤0.01% | 2175 |
|
|
2018
Q1 | $4.4M | Sell |
71,545
-3,216
| -4% | -$194K | ﹤0.01% | 2416 |
|
|
2017
Q4 | $4.37M | Sell |
74,761
-2,549
| -3% | -$161K | ﹤0.01% | 2422 |
|
|
2017
Q3 | $4.49M | Buy |
77,310
+5,761
| +8% | +$621K | ﹤0.01% | 2387 |
|
|
2017
Q2 | $8.66M | Buy |
71,549
+3,247
| +5% | +$376K | ﹤0.01% | 2054 |
|
|
2017
Q1 | $7.72M | Buy |
68,302
+6,312
| +10% | +$737K | ﹤0.01% | 2097 |
|
|
2016
Q4 | $6.74M | Sell |
61,990
-432
| -0.7% | -$51.5K | ﹤0.01% | 2170 |
|
|
2016
Q3 | $10.3M | Sell |
62,422
-3,994
| -6% | -$630K | ﹤0.01% | 1865 |
|
|
2016
Q2 | $9.48M | Sell |
66,416
-2,990
| -4% | -$436K | ﹤0.01% | 1880 |
|
|
2016
Q1 | $8.92M | Buy |
69,406
+1,906
| +3% | +$225K | ﹤0.01% | 1898 |
|
|
2015
Q4 | $10.1M | Sell |
67,500
-3,609
| -5% | -$611K | ﹤0.01% | 1840 |
|
|
2015
Q3 | $11.8M | Buy |
71,109
+5,382
| +8% | +$1.18M | ﹤0.01% | 1765 |
|
|
2015
Q2 | $15.9M | Buy |
65,727
+7,307
| +13% | +$1.95M | ﹤0.01% | 1642 |
|
|
2015
Q1 | $16.5M | Buy |
58,420
+13,958
| +31% | +$3.02M | ﹤0.01% | 1633 |
|
|
2014
Q4 | $6.94M | Sell |
44,462
-83,906
| -65% | -$15.5M | ﹤0.01% | 2132 |
|
|
2014
Q3 | $30.4M | Buy |
128,368
+92,038
| +253% | +$23.5M | 0.01% | 1162 |
|
|
2014
Q2 | $8.6M | Sell |
36,330
-4,641
| -11% | -$1.22M | ﹤0.01% | 2015 |
|
|
2014
Q1 | $13.5M | Sell |
40,971
-5,081
| -11% | -$1.71M | ﹤0.01% | 1703 |
|
|
2013
Q4 | $3.15M | Buy |
46,052
+2,372
| +5% | +$137K | ﹤0.01% | 2599 |
|
|
2013
Q3 | $3.02M | Buy |
43,680
+14,323
| +49% | +$707K | ﹤0.01% | 2567 |
|
|
2013
Q2 | $1.32M | Buy |
+29,357
| New | +$1M | ﹤0.01% | 3030 |
|
Bank of New York Mellon's ICPT Position: Q4 2023 in Review
Bank of New York Mellon sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 252,354 shares — an estimated $4.68M sold.
Bank of New York Mellon first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $30.4M in Q3 2014. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Bank of New York Mellon reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Bank of New York Mellon sold 252,354 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $4.68M.
- Bank of New York Mellon first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Bank of New York Mellon's Intercept Pharmaceuticals, Inc. position peaked at $30.4M in Q3 2014.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Bank of New York Mellon's 13F filing for Q4 2023, filed 29 Jan 2024.